Galderma Group AGGALDY -1.72%21 FCF Margin % is 19.93% as of Dec. 2025, which is 912% above its 10-year median of 1.97. GuruFocus rates GALDY with a GF Score™ of 21/100. The stock has 4 warning signs investors should review. Among 958 Drug Manufacturers companies, Galderma Group AG ranks better than 88.31% on this metric.
The historical rank and industry rank for Galderma Group AG's FCF Margin % or its related term are showing as below:
GALDY'
s FCF Margin % Range Over the Past 10 Years
Min: -1.26 Med: 1.97 Max: 19.67
Current: 19.67
During the past 5 years, the highest FCF Margin % of Galderma Group AG was 19.67%. The lowest was -1.26%. And the median was 1.97%.
GALDY's FCF Margin % is ranked better than 88.31% of 958
companies
in the Drug Manufacturers industry
Industry Median: 2.445
vs GALDY: 19.67
Galderma Group AG FCF Margin % Related Terms
Galderma Group AG FCF Margin % Historical Data
* Premium members only.
The historical data trend for Galderma Group AG's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Galderma Group AG's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Galderma Group AG FCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Galderma Group AG's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Galderma Group AG's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Galderma Group AG (GALDY) has a FCF Margin % of 19.93% as of Dec. 2025. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Galderma Group AG and its competitors. This is 912% above median its historical median of 1.97. According to the industry distribution chart, Galderma Group AG ranks #112 out of 958 companies in the Drug Manufacturers industry, placing it in the top 11.7%.
Is Galderma Group AG's FCF Margin % too high?
Galderma Group AG's current FCF Margin % of 19.93% is 912% above median its 10-year median of 1.97. The Drug Manufacturers industry median FCF Margin % is 2.45. Galderma Group AG's value of 19.93% is 715.1% above this industry median. Based on the distribution chart, Galderma Group AG ranks #112 out of 958 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Galderma Group AG has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Galderma Group AG's FCF Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Galderma Group AG ranks #112 out of 958 companies for FCF Margin %. This places Galderma Group AG in the top 12% of its industry — outperforming the majority of peers. The industry median FCF Margin % is 2.45. Galderma Group AG's value of 19.93% is 715.1% above this benchmark. While the company's 10-year median is 1.97 vs. the industry median of 2.45, Galderma Group AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Drug Manufacturers company?
The median FCF Margin % among Drug Manufacturers companies is 2.45, based on 958 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Galderma Group AG's current FCF Margin % of 19.93% is 715.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Galderma Group AG and its competitors. For the Drug Manufacturers industry, the median FCF Margin % is 2.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Galderma Group AG's current FCF Margin % is 19.93%, which is 912% above median its own 10-year median of 1.97. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Galderma Group AG stock overvalued right now?
Galderma Group AG (GALDY) has a current FCF Margin % of 19.93%. The current FCF Margin % is 19.93%, which is 912% above median its 10-year median of 1.97 and 715.1% above the Drug Manufacturers industry median of 2.45. Galderma Group AG's overall GF Score™ is 21/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Galderma Group AG (GALDY), the current FCF Margin % is 19.93% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Galderma was formed in 1981 as a joint venture between Nestle and L'Oreal. It subsequently became a subsidiary of Nestle, called Nestle Skin Health, before being carved out and launched as a stand-alone company in 2019, acquired by a consortium led by Sweden-based EQT fund. The company went public in March 2024 and is listed on the SIX Swiss exchange. Galderma's science-based portfolio spans multiple dermatology categories, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. It derives around 40% of net sales from the US and employs more than 7,500 people.
21GF Score
Get the complete analysis for GALDY
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GALDY has been successfully added to your 